Cylene Pharmaceuticals Initiates Phase II Clinical Trial Of Quarfloxin (CX-3543) In Patients With Carcinoid/Neuroendocrine Tumors

Cylene Pharmaceuticals announced the initiation of a Phase II clinical trial of quarfloxin (CX-3543) in patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant cancers arising from neural crest cells. “Quarfloxin (CX-3543) is a small molecule that disrupts a protein:rDNA complex that forms in the abnormal nucleoli of cancer cells, thereby selectively inducing apoptotic cell death in cancers,” said Dr.

More: continued here

Filed under: Endocrinology on December 19th, 2008